

**Ludwig Presence at 2017 Society for Neuro-Oncology
Annual Meeting**

Ludwig Scientist(s)	Affiliation(s)	Session Date/ Time	Session Type	Session Title	Presentation/Abstract Title
Thursday, November 16					
Paul Mischel	Ludwig San Diego	10:20 - 10:45am	Concurrent breakout session: Tumor biology and therapy	Biology of Resistance	The impact of tumor metabolic reprogramming on therapeutic resistance
Friday, November 17					
Frank Furnari (session chair)	Ludwig San Diego	7:00 - 8:30am	Sunrise Session	Therapeutic Opportunities Presented by Dysregulated Cell Signaling Mechanisms	7:00 - 7:25am: Leaders and followers in brain tumor heterogeneity
W.K. Alfred Yung	Ludwig Scientific Advisory Committee	9:05 - 9:35am	Plenary Session	Keynote Presentation	Introduction to the Moonshot Program
Irv Weissman, Siddhartha Mitra, Sam Cheshier**	Ludwig Stanford	4:20 - 4:25pm	Concurrent Session 3C	Microenvironment/Angiogenesis/Invasion	A potent microglial response to blocking TMIC-04 the CD47-Sirpα anti-phagocytic axis overcomes deficient macrophage recruitment during anti-CD47 immunotherapy against glioblastoma
Amy Thorne*, Frank Furnari**	Ludwig San Diego	4:45 - 4:50pm	Concurrent Session 3C	Microenvironment/Angiogenesis/Invasion	EGFR extracellular domain point mutant A289V: A therapeutically targetable driver of glioblastoma invasion

*scientist is lead author

**scientist is senior author

Saturday, November 18					
Web Cavenee (award recipient)	Ludwig Institute	11:20 - 11:25am	Lifetime Achievement Award		
Sunday, November 19					
Tomoyuki Koga*, Jorge Benitez, Alison Parisian, Kristen Turner, Amy Thorne, Ciro Zanca, Paul Mischel, Web Cavenee, Frank Furnari**	Ludwig San Diego, Ludwig Institute	11:00 - 11:10am	Concurrent Session 8B	Stem Cells	CRISPR/Cas9-edited human neural stem cells give rise to brain tumors resembling glioblastomas
Andrew Park, Paul Schwarzenberger, Toni Ricciardi, Mary Macri, Aileen Ryan, Ralph Venhaus**	Ludwig Clinical Trials Management	11:05-11:10am	Concurrent Session 8C	Immunology - Preclinical and Clinical II	Phase 2 study to evaluate the clinical efficacy and safety of durvalumab [DUR] in patients with bevacizumab (BEV)- refractory recurrent glioblastoma (GBM)

*scientist is lead author

**scientist is senior author